Iluvien approved in Australia for DME

The Iluvien implant has received regulatory approval from the Australian Therapeutic Goods Administration for the treatment of diabetic macular edema, Alimera Sciences announced.
Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) is approved in DME patients who have previously been treated with corticosteroids and did not have a clinically significant rise in intraocular pressure, according to a company press release.
“With this approval, we continue to execute on our strategy to grow Iluvien sales in existing markets and introduce the product in new territories to maximize the

Full Story →